Skip to main content
Equibles
IRWD logo

IRWD · Ironwood Pharmaceuticals Inc · Webcasts, Transcripts & Audio

Track IRWD — free

Use IRWD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IRWD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.76 -0.01 (-0.13%)
Russell 2000 member Rebalance outlook locked
Market Cap
$682.44M
Shares
165.24M
Volume · Oct 2 361.06K Avg daily vol (3M) 2.11M

Ironwood Pharmaceuticals Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Ironwood Pharmaceuticals Inc (IRWD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲0.4% $117.13M $41.37M '21 Q4 22-02-17 ▲9.8% $97.53M $38.80M '22 Q1 22-05-05 ▼6.5% $97.23M $37.08M '22 Q2 22-08-04 ▲4.7% $108.64M $50.32M '22 Q3 22-11-03 ▼8.5% $107.20M $48.87M '22 Q4 23-02-16 ▲6.7% $104.06M $45.71M '23 Q1 23-05-22 ▲10.4% $107.38M −$1.06B '23 Q2 23-08-08 ▲4.7% $113.74M $15.32M '23 Q3 23-11-09 ▲9.7% $117.55M −$1.09M '23 Q4 24-02-15 ▼28% $74.88M −$4.16M '24 Q1 24-05-09 ▼12.1% $94.40M −$860,000 '24 Q2 24-08-08 ▼19.5% $91.59M $3.65M '24 Q3 24-11-07 ▼23% $90.55M $2.26M '24 Q4 25-02-27 ▼47.3% $47.71M −$2.28M '25 Q4 26-02-25 ▲158.9% $106.51M $40.77M '26 Q1 26-05-07 LATEST ▲32.6% $113.04M $51.29M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Ironwood Pharmaceuticals Inc (IRWD) Q2 2026 Earnings Call
Revenue
$113.04M
▲ 32.6% YoY
Diluted EPS
$0.31
▲ 121.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Ironwood Pharmaceuticals Inc (IRWD) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Ironwood Pharmaceuticals Inc (IRWD) Q1 2026 Earnings Call Transcript
Confident tone Apraglutide / SBS-IF opportunity Linzess commercial performance Pricing and gross-to-net dynamics
Revenue
$106.51M
▲ 158.9% YoY
Diluted EPS
$0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Transcript
Confident tone Aproglutide STARS II confirmatory Phase III trial LINZESS commercial performance and market leadership 2026 financial guidance and EBITDA growth
Revenue
$47.71M
▼ 47.3% YoY
Diluted EPS
$-0.01
▼ 200% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q4
2025-02-27
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Transcript
Positive tone Short bowel syndrome commercial opportunity Apraglutide NDA progress LINZESS franchise
Revenue
$90.55M
▼ 23% YoY
Diluted EPS
$0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Transcript
Positive tone LINZESS commercial performance Apraglutide NDA and launch Profit and cash flow maximization
Revenue
$91.59M
▼ 19.5% YoY
Diluted EPS
$0.02
▼ 77.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Transcript
Positive tone LINZESS prescription demand Apraglutide NDA submission Apraglutide clinical profile and STARS Phase 3
Revenue
$94.40M
▼ 12.1% YoY
Diluted EPS
$-0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Ironwood Pharmaceuticals Inc (IRWD) Q1 2024 Earnings Call Transcript
Confident tone Apraglutide Phase III STARS results LINZESS commercial performance Apraglutide regulatory and launch planning
Revenue
$74.88M
▼ 28% YoY
Diluted EPS
$-0.03
▼ 112% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Ironwood Pharmaceuticals Inc (IRWD) Q4 2023 Earnings Call Transcript
Confident tone Apraglutide / STARS Phase 3 in short bowel syndrome LINZESS commercial performance Pipeline catalysts and upcoming data readouts
Revenue
$117.55M
▲ 9.7% YoY
Diluted EPS
$-0.01
▼ 103.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Ironwood Pharmaceuticals Inc (IRWD) Q3 2023 Earnings Call Transcript
Revenue
$113.74M
▲ 4.7% YoY
Diluted EPS
$0.09
▼ 67.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Ironwood Pharmaceuticals Inc (IRWD) Q2 2023 Earnings Call Transcript
Revenue
$107.38M
▲ 10.4% YoY
Diluted EPS
$-6.84
▼ 3357.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-22
Ironwood Pharmaceuticals Inc (IRWD) Q1 2023 Earnings Call Transcript
Revenue
$104.06M
▲ 6.7% YoY
Diluted EPS
$0.25
▲ 19% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-16
Ironwood Pharmaceuticals Inc (IRWD) Q4 2022 Earnings Call Transcript
Revenue
$107.20M
▼ 8.5% YoY
Diluted EPS
$0.27
▲ 8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Ironwood Pharmaceuticals Inc (IRWD) Q3 2022 Earnings Call Transcript
Revenue
$108.64M
▲ 4.7% YoY
Diluted EPS
$0.28
▼ 17.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Ironwood Pharmaceuticals Inc (IRWD) Q2 2022 Earnings Call Transcript
Revenue
$97.23M
▼ 6.5% YoY
Diluted EPS
$0.21
▼ 91.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Ironwood Pharmaceuticals Inc (IRWD) Q1 2022 Earnings Call Transcript
Revenue
$97.53M
▲ 9.8% YoY
Diluted EPS
$0.21
▼ 16% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
Ironwood Pharmaceuticals Inc (IRWD) Q4 2021 Earnings Call Transcript
Revenue
$117.13M
▲ 0.4% YoY
Diluted EPS
$0.25
▼ 7.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Ironwood Pharmaceuticals Inc (IRWD) Q3 2021 Earnings Call Transcript
Revenue
$103.75M
▲ 0.3% YoY
Diluted EPS
$0.34
▲ 61.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Ironwood Pharmaceuticals Inc (IRWD) Q2 2021 Earnings Call Transcript
Revenue
$104.03M
▲ 16.3% YoY
Diluted EPS
$2.39
▲ 1393.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Ironwood Pharmaceuticals Inc (IRWD) Q1 2021 Earnings Call Transcript
Revenue
$88.84M
▲ 11.1% YoY
Diluted EPS
$0.25
▲ 1150% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
Ironwood Pharmaceuticals Inc (IRWD) Q4 2020 Earnings Call Transcript
Revenue
$116.68M
▼ 7.6% YoY
Diluted EPS
$0.27
▼ 10% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Transcript
Revenue
$103.47M
▼ 21.1% YoY
Diluted EPS
$0.21
▲ 61.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Ironwood Pharmaceuticals Inc (IRWD) Q2 2020 Earnings Call Transcript
Revenue
$89.43M
▼ 12.5% YoY
Diluted EPS
$0.16
▲ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ironwood Pharmaceuticals Inc (IRWD) Q1 2020 Earnings Call Transcript
Revenue
$79.94M
▲ 16.3% YoY
Diluted EPS
$0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 webcasts
Key facts CIK 1446847 CUSIP 46333X108 13F (30d) 5 filings 5 filers Visit website Investor relations